Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders
DUNDEE, UK; 2nd May, 2023 – Tay Therapeutics, focused on developing small molecules for oncology and severe inherited diseases, today announced that it has entered into an exclusive license agreement with VYNE Therapeutics Inc. (Nasdaq: VYNE), a US-based biotech focused on developing proprietary, innovative and differentiated therapies in immuno-inflammatory diseases, for its oral BET inhibitor, TAY-B2 (VYN202).
